Please login to the form below

Not currently logged in
Email:
Password:

Elan names new chairman

Elan Corporation has named former GSK vice chairman pharmaceuticals, Robert A Ingram, as chairman effective January 2011

Neuroscience-focused biotechnology company, Elan Corporation, has named former GlaxoSmithKline (GSK) vice chairman pharmaceuticals, Robert A Ingram, as chairman effective January 26, 2011.

Ingram, who was also formerly CEO of Glaxo Wellcome, will succeed Kyran McLaughlin, who announced his intention to step down as non-executive chairman for Ireland-based Elan in April 2010.

Speaking on the announcement, McLaughlin said: "With top level leadership experience at Glaxo Wellcome and GlaxoSmithKline, Bob has a proven track record of successful leadership and a deep understanding of the industry overall. I am proud to be turning over the chairmanship to such a capable and high integrity leader and know that he will make many contributions as the company continues to develop and advance."

Ingram currently serves on several boards of directors already, including Allergan, Edwards Lifesciences Corporation and Valeant Pharmaceuticals. He has also acted as an advisor to GSK CEO, Andrew Witty, since January 2010.

Commenting on his appointment, Ingram said: "I am impressed with the progress [Elan] has made over the past several years in advancing the science, improving its financial performance, and constructing unique and far reaching collaborations which will enable the company to continue to invest in science and innovate within the world of novel therapeutic advances.

"I look forward to working with the board and the management team to deliver long term benefits to science, patients and shareholders."

7th December 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics